AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03878524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO
Study NCT03878524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vismodegib
Description: Given PO
Study NCT03878524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Given PO
Study NCT00287859 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topotecan hydrochloride
Description: intravenously (IV) over 30 minutes on days 1, 8, 15, 22, and 29.
Study NCT04400760 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: DAPA Tx
Description: The intervention, dapagliflozin will be administered 10mg per oral daily for two weeks.
Study NCT01492972 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Consists of:~1. Conformal Proton Radiation Dose: 2.5 Gy (RBE) five days a week in 28 treatments over 5.5-6.5 weeks (total dose: 70 Gy (RBE))~2. High Dose Radiation with IMRT alone: 1.8 Gy five days a week in 45 treatments over 9-10 weeks (total dose: 81 Gy)~3. Intraoperative LDR Brachytherapy and IMRT: 100Gy Pad103 implant and IMRT 1.8 Gy five days a week in 25 treatments over 5-6 weeks (total dose: 45 Gy)
Study NCT01492972 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation
Description: Consists of:~1. Conformal Proton Radiation Dose: 2.5 Gy (RBE) five days a week in 28 treatments over 5.5-6.5 weeks (total dose: 70 Gy (RBE))~2. High Dose Radiation with IMRT alone: 1.8 Gy five days a week in 45 treatments over 9-10 weeks (total dose: 81 Gy)~3. Intraoperative LDR Brachytherapy and IMRT: 100Gy Pad103 implant and IMRT 1.8 Gy five days a week in 25 treatments over 5-6 weeks (total dose: 45 Gy)
Study NCT01492972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Androgen Suppression Therapy
Description: Androgen suppression will begin 8 - 10 weeks prior to the start of RT for a total of 6 (+/- 2) months. Luteinizing Hormone-Releasing Hormone (LHRH) agonist therapy will consist of analogs approved by the FDA (or by Health Canada for Canadian institutions)
Study NCT03697850 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab after adjuvant radio-chemotherapy for the treatment of patients with muscle-invasive bladder cancer not eligible for radical cystectomy
Study NCT03838744 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard arm: Trabectedin in monotherapy
Description: Trabectedin in monotherapy
Study NCT03838744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental arm: Trabectedin + Olaparib
Description: Trabectedin given in combination to olaparib
Study NCT02202564 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LT
Description: Orthotopic LT
Study NCT01644539 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Water with guar gum - Non Caloric
Description: Infusion 500 ml of water with 3 gram of guar gum through a naso-gastric tube directly into stomach during a fMRI scan.
Study NCT02202564 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LT
Description: Orthotopic LT
Study NCT02202564 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADV-TK
Study NCT02202564 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ganciclovir
Study NCT01644539 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Chocolate milk - Oral Caloric
Description: Ingestion of 500 ml of commercially available chocolate milk (Per 100mL; energy content of 354 kJ, 84 kcal, 3.5 g proteins, 12 g mono and disaccharide, 2.5 fat g, 0.5 g fibers) through a tube in the mouth during a fmri scan.
Study NCT01644539 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Chocolate milk - Intra Gastric Caloric
Description: Infusion of 500 ml of commercially available chocolate milk (Per 100mL; energy content of 354 kJ, 84 kcal, 3.5 g proteins, 12 g mono and disaccharide, 2.5 fat g, 0.5 g fibers) through a naso-gastric tube directly into stomach during a fMRI scan.
Study NCT01463488 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR113945
Description: Pharmaceutical form:Injection~Route of administration: Intra-articular
Study NCT04505761 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: Participants will use a Virtual Reality headset with a range of applications applicable for rehabilitation after COVID-19. Applications target physical, psychological, and cognitive rehabilitation. VR headset will be used for six weeks first at the physiotherapist's practice, and when possible, at home.
Study NCT03401203 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rotational atherectomy followed by balloon angioplasty
Description: Percutaneous coronary intervention
Study NCT03401203 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Balloon angioplasty
Description: Percutaneous coronary intervention
Study NCT06268470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desloratadine plus cilostazol and dipyridamole
Description: Desloratadine 20 mg/day plus cilostazol 150 mg/day and dipyridamole 50 mg/day
Study NCT06268470 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desloratadine
Description: Desloratadine 20 mg/day
Study NCT06268470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desloratadine
Description: Desloratadine 20 mg/day
Study NCT03764969 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: standard smoking cessation program (SCP)
Description: Each subject will receive standard SCP as group treatment once a week (1 hour) over six weeks. This group therapy is based on behavioural therapy and a psycho-educational approach (for more details see Batra \& Buchkremer 2004), and will be carried out by a qualified therapist.
Study NCT03764969 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: standard smoking cessation program (SCP)
Description: Each subject will receive standard SCP as group treatment once a week (1 hour) over six weeks. This group therapy is based on behavioural therapy and a psycho-educational approach (for more details see Batra \& Buchkremer 2004), and will be carried out by a qualified therapist.
Study NCT03764969 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive remediation treatment (CRT)
Description: Cognitive remediation treatment (CRT) employing a chess-based battery of tasks two times per week over six weeks as a group treatment in our outpatient clinic (60 min duration per session).
Study NCT03764969 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Implicit computer-based habit-modifying training (ICHT)
Description: Implicit computer-based habit-modifying training (ICHT), applied twice a week for six weeks. In this training, the participants perform a two-part training. First, a subliminal presentation (20 ms) of negative valenced primes before smoking-cues in context and secondly, a subliminal presentation of positive valenced primes before potentially reinforcing events.
Study NCT00165828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zonegran
Description: Intravenous injection; initial daily dose of 50 mg zonisamide (2x25 mg) in both treatment groups; following a prospective or retrospective baseline phase of 8 weeks the study drug will be administered twice daily during 16 consecutive weeks.
Study NCT02466724 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aiddly (Web Site)
Description: A website designed to better educate patients on how to prepare for their colonoscopies
Study NCT03720366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enasidenib
Description: enasidenib
Study NCT01463488 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Pharmaceutical form:Injection~Route of administration: Intra-articular
Study NCT01596478 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: Participants will receive Treatment as Usual, on an individual basis, for 60-minutes once per week for 12 weeks.
Study NCT03720366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arm 1 probes
Description: caffeine, dextromethorphan, flurbiprofen, midazolam, and omeprazole
Study NCT01405118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin/CP-690,550
Description: Single oral 500 mg dose of metformin on Days 1 and 4 and multiple oral 30 mg doses of CP-690,550 every 12 hours on Days 2-4.
Study NCT03101514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kanglaite
Description: Kanglaite injection 200ml is injected intravenous from the first day to the last day of radiotherapy.
Study NCT03101514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chemotherapy
Description: Cisplatin 80-100mg/m2 was used every 3 weeks during radiotherapy.
Study NCT02503774 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oleclumab
Description: Participants will receive IV infusion of oleclumab as stated in arms' description.
Study NCT03720366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arm 2 Probes
Description: digoxin and rosuvastatin
Study NCT03720366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arm 3 probes
Description: pioglitazone
Study NCT01596478 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Motivational Behavior Therapy
Description: Participants will receive a combined motivational and cognitive-behavioral therapy, on an individual basis, for 60-minutes once per week for 12 weeks.
Study NCT01596478 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 12-week wait list
Description: Participants will be randomly assigned to start treatment immediately or to go on a 12-week wait list (where they will start treatment 12 weeks from day of consent).
Study NCT06346002 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based intervention
Description: The MBI program implemented comprised ten weekly sessions. Please refer to the arm/group descriptions for further details.
Study NCT01673698 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ReShape Duo balloon
Study NCT01673698 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diet counseling
Study NCT01673698 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Diet counseling
Study NCT01673698 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise counseling
Study NCT01673698 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Exercise counseling
Study NCT00877357 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Shan 5
Description: Diphtheria, tetanus, whole cell pertussis, recombinant hepatitis B and Hib tetanus toxoid conjugate pentavalent liquid combination vaccine
Study NCT02503774 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Participants will receive IV infusion of durvalumab as stated in arms' description.
Study NCT01912638 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ologen Collagen Matrix
Description: Ologen is a porous collagen-glycosaminoglycan matrix that decrease early postoperative scarring after penetrating anti-glaucomatous surgery by randomized collagen deposition and microcyst formation. Implantation of Ologen Collagen Matrix in trabeculectomy was performed.
Study NCT01912638 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Provisc
Description: Provisc is an cohesive viscoelastic.
Study NCT01510574 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: 3 x 200mcg tablets of oral misoprostol
Study NCT01510574 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 3 x placebo tablets resembling misoprostol taken orally
Study NCT01937702 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 0.9% NaCl (sodium chloride)
Study NCT00043602 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard interpersonal psychotherapy (IPT)
Description: Participants will receive 12 sessions of IPT over 12 weeks.
Study NCT00043602 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinician managed interpersonal psychotherapy (CM-IPT)
Description: Participants will receive 12 sessions of CM-IPT over 1 year.
Study NCT00194025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valproate
Description: Enrolled individuals received adjunctive, open-label valproate semisodium, initially started as valproate semisodium delayed -release 250 mg at bedtime for two weeks, then changed to valproate semisodium extended- release 500 mg at bedtime. Medication was administered on an outpatient/ambulatory basis, and adjusted as tolerated to target serum levels of 50-100 µg/mL. In cases where sedation or other side effects occurred, dosage was reduced. Valproate semisodium was prescribed in a single dose at bedtime.
Study NCT00448760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Intravenously, 25 mg/m2, over 30 minutes, 2 cycles
Study NCT00448760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Floxuridine
Description: Intravenuosly, 110mg/kg, continuous infusion over 24 hours, 2 cycles
Study NCT03659578 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Concurrent chemotherapy
Description: Concurrent chemotherapy consists of weekly docetaxel(25mg/㎡) and nedaplatin(25mg/㎡), each of 1 day's duration.
Study NCT00448760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Intravenuosly, 500mg/m2, continuous infusion over 24 hours, 2 cycles
Study NCT00448760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Intravenously, 85 mg/m2, over 2 hours, 2 cycles
Study NCT00448760 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Microarray analysis
Description: Analysis of tumor for pathologic response to protocol therapy
Study NCT00448760 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: reverse transcriptase-polymerase chain reaction
Description: Analysis of tumor for pathologic response to protocol therapy
Study NCT00448760 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional surgery
Description: Surgical removal of tumor for correlative studies
Study NCT01911234 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TNF-Kinoid
Description: IM administration
Study NCT01911234 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IM administration
Study NCT03659578 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: split-course radiotherapy
Description: Patient was administered with 51 Gy in 17 fractions or 40 Gy in 10 fractions as the first course followed by a break of four weeks. Patients without disease progression had a dose of 15 Gy in 5 fractions or 24 Gy in 6 fractions as a boost
Study NCT03659578 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thymosin alpha 1
Description: subcutaneous injections of thymosin once a week,1.6mg each time from the start of radiation to 2 months after the end of radiation.
Study NCT00624845 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OMS103HP
Description: Maximum 6 bags of OMS103HP irrigation solution
Study NCT00624845 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Maximum of 6 bags of vehicle irrigation solution
Study NCT02356237 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No episiotomy
Description: Avoidance of episiotomy
Study NCT03886480 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SaeboVR
Description: Use of the SaeboVR rehabilitation system for approximately 1 hour, 3 times per week for 4 weeks. Each intervention session will consist of the participant engaging in a series of virtual occupations involving their affected upper extremity and will include a 5 minute warm up activity followed by 3, 15 minute sessions of virtual occupation practice separated by 2, 5 minute breaks. The virtual occupations will include: grocery shopping, grocery storage, breakfast preparation, pet shopping, pet feeding, pet bathing, garden planting, garden harvesting, dinner preparation, closet organizing, and soup kitchen volunteering.
Study NCT02296320 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MEDI4893
Description: Participants will receive a single IV dose of MEDI4893 2000 or 5000 mg on Day 1 of the study.
Study NCT02296320 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive a single IV dose of placebo matched to MEDI4893 on Day 1 of the study.
Study NCT03074994 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peri-articular TXA (15 mg/kg)
Description: combined with multimodal local anesthetic infiltration (0.5% bupivacaine 100 mg, morphine sulfate 5 mg, 0.1% epinephrine 0.6 mg, and ketorolac 30 mg) mixed NSS up to 75 mL
Study NCT03074994 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intraarticular TXA 2 g (40 mL)
Description: inject separate from multimodal local anesthetic infiltration (0.5% bupivacaine 100 mg, morphine sulfate 5 mg, 0.1% epinephrine 0.6 mg, and ketorolac 30 mg mixed NSS up to 75 mL)
Study NCT03074994 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TXA combined with multimodal local anesthetic infiltration inject into peri-articular area
Description: (Anterior soft tissue 25 mL+Medial gutter area 25 mL+Lateral gutter area 25 mL) prior to capsular closure and tourniquet deflation
Study NCT02031614 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Phlebotomy
Description: Withdrawal of 500 mL of whole blood.
Study NCT01900366 — intervention group
Intervention type: PROCEDURE
Intervention: Fat Biopsy
Description: Fat biopsy
Study NCT03074994 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TXA 40 mL inject into intraaricular knee capsule
Description: after multimodal local anesthetic infiltration (Anterior soft tissue 25 mL+Medial gutter area 25 mL+Lateral gutter area 25 mL) prior to tourniquet deflation
Study NCT00530530 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP8825
Description: oral
Study NCT03187860 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ALI culture
Description: Air-liquid-interface cell cultures will be derived from bronchial biopsy specimens. We are expecting several replicate cell lines from each biopsy specimen.
Study NCT02497716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (Xarelto, BAY59-7939
Description: Single dose of reconstituted rivaroxaban granules
Study NCT05623553 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Picterus Jaundice Pro
Description: Use Picterus Jaundice Pro, a smartphone app that is used to take photo of the newborns skin, where the Picterus calibration card is place.
Study NCT02556138 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ORBERA Intragastric Balloon
Description: The ORBERA Intragastric Balloon will be placed in the stomach endoscopically through a catheter under conscious sedation. The procedure takes about 20 minutes to complete. The balloon will stay in place for 6 months and then it will be removed endoscopically.
Study NCT01541631 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Praziquantel and Albendazole
Description: Praziquantel Tablet - 40mg/kgBWT given once Albendazole Tablet - 400mg once
Study NCT01541631 — intervention group
Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: Praziquantel and Albendazole
Description: Praziquantel- 40mg/kgBWT Albendazole - 400mg once
Study NCT02383160 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bioventus Exogen 4000: Low-intensity pulsed ultrasound
Description: Active low-intensity pulsed ultrasound
Study NCT05013489 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness and intercare based intervention
Description: Eight week online program based on mindfulness, compassion and intercare intervention. A two hour synchronic online session every week plus daily homework based on meditation and journaling exercises.~The topics covered in the program are mindfulness meditation, cognitive behavioral therapy exercises, gratitude and acceptance, compassion and self compassion exercises, conservation of resources theory and intercare.
Study NCT00530530 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral
Study NCT03154151 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Cognitive-Behavioral Therapy
Description: Each participant will complete writing assignments focusing on how their experiences during the 9/11 attacks or the WTC recovery effort continue to affect their life, and the therapist will provide written responses and guidance within two work days, through the secure Web platform. Participants will be asked to complete one to two 45-minute writing assignments per week, over a six-week period (11 in total). Participants are asked not to begin new psychotherapy or medication with an outside therapist or doctor during the study.
Study NCT03154151 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Online Supportive Therapy
Description: Each participant will complete writing assignments focusing on problems and stressors that are currently affecting their life, and the therapist will provide written responses and guidance within two work days, through the secure Web platform. Participants will be asked to complete one to two 45-minute writing assignments per week, over a six-week period (11 in total). Participants are asked not to begin new psychotherapy or medication with an outside therapist or doctor during the study.